Serum and CSF Neurofilament Light Levels Predict Long-Term Outcomes in Multiple Sclerosis Patients (S50.005)

Conclusions:Serum and CSF NfL in relapsing MS patients are associated with long-term clinical outcome. NfL is an attractive candidate biomarker for risk/severity stratification in MS.Study Supported by: RCT supported by NIH NINDS RO1-26321, NMSS RG3099 and Biogen; F/U studies supported by Biogen; sample analysis supported by the Swiss National Science Foundation.Disclosure: Dr. Kuhle holds stock and/or stock options in Bayer (Schweiz) AG, Genzyme, Novartis, Protagen AG, and Roche. Dr. Plavina has nothing to disclose. Dr. Barro has nothing to disclose. Dr. Sangurdekar has nothing to disclose. Dr. Singh has nothing to disclose. Dr. DeMoor has nothing to disclose. Dr. Engle has nothing to disclose. Dr. Fisher has nothing to disclose. Dr. Kappos has reveived personal compensation for activities with University Hospital Basel as an advisory board member. Dr. Kappos has received research support from Swiss Multiple Sclerosis Society, Swiss National Research Foundation, European Union, Gianni Rubatto Foundation, Novartis Research Foundation, and Roche Research Foundation. Dr. Rudick has received personal compensation for activities with Biogen Idec. Dr. Rudick holds stock and/or stock options in Biogen Idec. Dr. Goyal has nothing to disclose.

Source: Neurology - April 17, 2017 Category: Neurology Authors: Kuhle, J., Plavina, T., Barro, C., Sangurdekar, D., Singh, C., DeMoor, C., Engle, B., Fisher, E., Kappos, L., Rudick, R., Goyal, J. Tags: MS Novel Therapeutics and Animal Models Source Type: research